Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
Total Valuation
ACADIA Pharmaceuticals has a market cap or net worth of $3.65B. The enterprise value is $2.85B.
Market Cap$3.65B
Enterprise Value$2.85B
Share Statistics
ACADIA Pharmaceuticals has 168,712,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding168,712,220
Owned by Insiders23.64%
Owned by Institutions0.02%
Financial Efficiency
ACADIA Pharmaceuticals’s return on equity (ROE) is 0.31 and return on invested capital (ROIC) is 24.92%.
Return on Equity (ROE)0.31
Return on Assets (ROA)0.19
Return on Invested Capital (ROIC)24.92%
Return on Capital Employed (ROCE)0.29
Revenue Per Employee1.47M
Profits Per Employee346.79K
Employee Count653
Asset Turnover0.81
Inventory Turnover3.73
Valuation Ratios
The current PE Ratio of ACADIA Pharmaceuticals is 14.5. ACADIA Pharmaceuticals’s PEG ratio is -0.03.
PE Ratio14.5
PS Ratio3.17
PB Ratio4.15
Price to Fair Value4.15
Price to FCF19.34
Price to Operating Cash Flow20.16
PEG Ratio-0.03
Income Statement
In the last 12 months, ACADIA Pharmaceuticals had revenue of 957.80M and earned 226.45M in profits. Earnings per share was 1.37.
Revenue957.80M
Gross Profit875.96M
Operating Income230.79M
Pretax Income258.07M
Net Income226.45M
EBITDA100.16M
Earnings Per Share (EPS)1.37
Cash Flow
In the last 12 months, operating cash flow was 198.95M and capital expenditures -1.14M, giving a free cash flow of 197.81M billion.
Operating Cash Flow198.95M
Free Cash Flow197.81M
Free Cash Flow per Share1.17
Dividends & Yields
ACADIA Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.15
52-Week Price Change23.54%
50-Day Moving Average22.62
200-Day Moving Average20.56
Relative Strength Index (RSI)54.03
Average Volume (3m)1.98M
Important Dates
ACADIA Pharmaceuticals upcoming earnings date is Mar 2, 2026, After Close (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateMar 2, 2026
Ex-Dividend Date―
Financial Position
ACADIA Pharmaceuticals as a current ratio of 2.38, with Debt / Equity ratio of 6.85%
Current Ratio2.38
Quick Ratio2.32
Debt to Market Cap<0.01
Net Debt to EBITDA-2.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, ACADIA Pharmaceuticals has paid 31.62M in taxes.
Income Tax31.62M
Effective Tax Rate0.12
Enterprise Valuation
ACADIA Pharmaceuticals EV to EBITDA ratio is 27.69, with an EV/FCF ratio of 17.64.
EV to Sales2.90
EV to EBITDA27.69
EV to Free Cash Flow17.64
EV to Operating Cash Flow17.58
Balance Sheet
ACADIA Pharmaceuticals has $847.02M in cash and marketable securities with $43.03M in debt, giving a net cash position of $803.99M billion.
Cash & Marketable Securities$847.02M
Total Debt$43.03M
Net Cash$803.99M
Net Cash Per Share$4.77
Tangible Book Value Per Share$3.70
Margins
Gross margin is 91.97%, with operating margin of 24.10%, and net profit margin of 23.64%.
Gross Margin91.97%
Operating Margin24.10%
Pretax Margin26.94%
Net Profit Margin23.64%
EBITDA Margin10.46%
EBIT Margin8.80%
Analyst Forecast
The average price target for ACADIA Pharmaceuticals is $30.35, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$30.35
Price Target Upside34.47% Upside
Analyst ConsensusModerate Buy
Analyst Count18
Revenue Growth Forecast12.69%
EPS Growth Forecast100.80%